Investors
To download our documents
OSE Immunotherapeutics is listed since 30th March 2015 on the regulated market of Euronext Paris
FR0012127173
OSE
Continuous
22,910,181 shares as of June 30, 2025
Eligible to Long-Only Deferred Settlement Service
Annual financial results 2024
Half-year results 2025
General shareholders' meeting (subject to the evolution of ongoing legal proceedings)